Eli Lilly struck a deal with Repertoire Immune Medicines to develop tolerizing therapies for autoimmune diseases, a collaboration structured with an $85 million upfront payment and up to $1.84 billion in milestones plus royalties. The partnership will apply Repertoire’s Decode platform to identify antigen‑specific tolerizing candidates at scale. For Lilly, the deal bolsters its autoimmunity pipeline with a platform approach aimed at antigen‑selective modulation rather than broad immunosuppression. For Repertoire, the pact adds another big‑pharma validation of its discovery engine and supplies capital and development resources to move candidates toward clinical proof‑of‑concept.